eISSN: 2391-6052
ISSN: 2353-3854
Alergologia Polska - Polish Journal of Allergology
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Suplementy Zeszyty specjalne Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
Wyszukiwanie
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

without publication fees
4/2024
vol. 11
 
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:
streszczenie artykułu:
Opis przypadku

Efficacy of hydroxychloroquine and omalizumab in a patient with systemic lupus erythematosus, Hashimoto thyroiditis and refractory chronic spontaneous urticaria

Öner Özdemir
1
,
Ümmügülsüm Dikici
1
,
Sena Sultan Karaca
2

  1. Division of Pediatric Immunology and Allergy, Sakarya Training and Research Hospital, Sakarya University Medical Faculty, Sakarya, Türkiye
  2. Sakarya University Medical Faculty, Sakarya Training and Research Hospital, Sakarya, Türkiye
Alergologia Polska – Polish Journal of Allergology 2024; 11, 4: 335–338
DOI: https://doi.org/10.5114/pja.2024.145187
Data publikacji online: 2024/11/21
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


A 15-year-old girl was admitted to an external center 1 month ago with symptoms of generalized pruritus, rash and blistering all over the body, and swelling of the eyes and lips. The patient was started on desloratadine, but there was no improvement in her symptoms. She had been diagnosed with Hashimoto’s thyroiditis 4 years ago in the pediatric endocrinology department; she had been using levothyroxine since then, and her thyroid disease was under control. The dose of antihistamine treatment was increased and montelukast was added. The patient, who had Raynaud’s phenomenon, was diagnosed with systemic lupus erythematosus and hydroxychloroquine was started, but the symptoms of urticaria and angioedema did not decrease. The patient was then started on omalizumab and urticaria was controlled under hydroxychloroquine + omalizumab. In the third month of omalizumab discontinuation, the patient is receiving hydroxychloroquine and levothyroxine treatments and continues to be followed up, being in remission in terms of chronic spontaneous urticaria.


Termedia
O Wydawnictwie Oferty Newsletter Kontakt Praca
Polityka prywatności Polityka reklamowa Napisz do nas Nota prawna Regulamin
Na skróty
Czasopisma Aktualności Książki eBooki Konferencje i webinary
Serwisy
KONGRES TOP MEDICAL TRENDS Koronawirus Zalecenia i rekomendacje Lekarz POZ Kurier Medyczny Dermatologia Diabetologia e-Praktyka Leczenia Ran Ginekologia Neurologia Onkologia Pulmonologia Reumatologia Menedżer Zdrowia Warto wiedzieć
e-Akademia
e-Akademia Raka Płuca e-Akademia MAFLD e-Akademia Zaburzeń Mikrobioty e-Akademia POChP e-Akademia Chorób Naczyń e-Akademia Chorób Cywilizacyjnych Akademia Zapalenia typu 2 Akademia AZScience
© 2024 Termedia Sp. z o.o.
Developed by Bentus.